Drug Information

Drug General Information
Drug ID
D0N2KU
Former ID
DNC009881
Drug Name
PF-3409409
Drug Type
Small molecular drug
Indication Attention deficit hyperactivity disorder [ICD9: 314; ICD10:F90] Investigative [530265]
Formula
C17H21F3N2O
Canonical SMILES
C1CC(C1)CN(C2CCNC2)C(=O)C3=CC=CC=C3C(F)(F)F
InChI
1S/C17H21F3N2O/c18-17(19,20)15-7-2-1-6-14(15)16(23)22(11-12-4-3-5-12)13-8-9-21-10-13/h1-2,6-7,12-13,21H,3-5,8-11H2/t13-/m0/s1
InChIKey
SWADTMSKMJUFBO-ZDUSSCGKSA-N
PubChem Compound ID
44517677
Target and Pathway
Target(s) Sodium-dependent noradrenaline transporter Target Info Inhibitor [530265]
Muscarinic acetylcholine receptor M5 Target Info Inhibitor [530265]
Sodium-dependent dopamine transporter Target Info Inhibitor [530265]
Sodium-dependent serotonin transporter Target Info Inhibitor [530265]
Muscarinic acetylcholine receptor M4 Target Info Inhibitor [530265]
KEGG Pathway Calcium signaling pathway
Neuroactive ligand-receptor interaction
Cholinergic synapse
Regulation of actin cytoskeletonhsa04728:Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Amphetamine addiction
Alcoholismhsa04726:Serotonergic synapsehsa04080:Neuroactive ligand-receptor interaction
Regulation of actin cytoskeleton
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesisP00003:Alzheimer disease-amyloid secretase pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathwayP00001:Adrenaline and noradrenaline biosynthesis
Parkinson disease
Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Muscarinic acetylcholine receptor 2 and 4 signaling pathway
Pathway Interaction Database Alpha-synuclein signaling
Reactome Na+/Cl- dependent neurotransmitter transportersR-HSA-390648:Muscarinic acetylcholine receptors
G alpha (q) signalling eventsR-HSA-442660:Na+/Cl- dependent neurotransmitter transportersR-HSA-390648:Muscarinic acetylcholine receptors
G alpha (i) signalling events
WikiPathways Monoamine Transport
NRF2 pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compoundsWP58:Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
Regulation of Actin Cytoskeleton
GPCRs, Class A Rhodopsin-like
Gastrin-CREB signalling pathway via PKC and MAPK
GPCR ligand binding
GPCR downstream signalingWP727:Monoamine Transport
Dopaminergic Neurogenesis
Parkinsons Disease Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport
SIDS Susceptibility Pathways
Synaptic Vesicle Pathway
Serotonin Transporter ActivityWP58:Monoamine GPCRs
GPCR downstream signaling
References
Ref 530265Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. Epub 2009 Jul 2.Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.
Ref 530265Bioorg Med Chem Lett. 2009 Aug 15;19(16):4579-83. Epub 2009 Jul 2.Design, synthesis and evaluation of N-[(3S)-pyrrolidin-3-yl]benzamides as selective noradrenaline reuptake inhibitors: CNS penetration in a more polar template.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.